SELADELPAR

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Livdelzi®
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
GILEAD SCIENCES PTY LTD
Condition/indication:
(therapeutic use)
  • Primary biliary cholangitis (PBC)
Listing requested:
Please see meeting agenda for more information
Funding program:
Please see meeting agenda for more information
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
New listing (Matters arising/Matters outstanding)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
December 2025 PBAC meeting
Opportunity for consumer comment:
Open 04/02/2025 and close 28/05/2025 (see PBS Website)
PBAC meeting:
Held on 10/12/2025
4PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – December 2025
Case ID
a1190
Page last updated
30 April 2026
Return to the Medicine Status Listing
v.9.19